Part D Plans, Unlike Others, Prefer High List Price Drugs With Big Rebates

By John Wilkerson / January 24, 2020 at 2:20 PM
Unlike commercial and Medicaid plans, Medicare Part D plans favor high list-price drugs when identical low list-price drugs are available, according to Drug Channels CEO Adam Fein, who analyzed newly released data from IQVIA on market share of hepatitis C drugs . Drug makers blame rebates for rising list prices, and HHS considered banning rebates in Medicare before scrapping the proposal over concerns that it would lead to higher premiums. Brands raise list prices so they can buy favorable formulary...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.